| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/19/2005 | CN1565471A Breviscapine drop pill |
| 01/19/2005 | CN1565465A Injection preparation containing breviscapine active component and its preparation method |
| 01/19/2005 | CN1565464A Haw effective part and its extracting method and uses |
| 01/19/2005 | CN1565448A Nitrendipine dispersion tablet and method for making same |
| 01/19/2005 | CN1565438A Use of 5-hydroxymethyl furfural in preparation of drug for nerve system |
| 01/19/2005 | CN1565437A Verapamil hydrochloric acid drop pill and its preparation method |
| 01/19/2005 | CN1565433A Hypocrellin water-soluble nanogranule and its uses |
| 01/19/2005 | CN1565430A Allicin cyclodextrin clathrate compound, formulation and its preparation method |
| 01/19/2005 | CN1185250C Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/19/2005 | CN1185243C Tetrahydroxydiphenylethylene glycosides compounds for preventing and curing angiocardiopathy and cerebrovascular diseases |
| 01/19/2005 | CN1185233C Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/19/2005 | CN1185232C Inhibitors of alpha L beta 2 mediated cell adhesion |
| 01/19/2005 | CN1185229C 3-indolyl-4-phenyl-1H-pyrrole-2, 5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
| 01/19/2005 | CN1185227C Novel compounds |
| 01/19/2005 | CN1185226C Intermediate for preparing benzothiophene amide derivate |
| 01/19/2005 | CN1185215C Substituted glutarimides and use as IL-12 production inhibitors thereof |
| 01/19/2005 | CN1185213C Azetidine derivatives, preparation and pharmaceutical compositions thereof |
| 01/19/2005 | CN1185211C Benzamide derivatives for the treatment of diseases resulted from cytokines |
| 01/19/2005 | CN1185007C Fat reducing and thrombosis dissolving medicine |
| 01/19/2005 | CN1185002C Medicine for treating heart disease |
| 01/19/2005 | CN1184973C Thrombolytic leech soft capsule and its preparing method |
| 01/19/2005 | CN1184971C Pharmaceutical combination preparations |
| 01/19/2005 | CN1184964C Use of carbonylamino derivatives against CNS disorders |
| 01/19/2005 | CN1184962C Sertraline oral condensate |
| 01/18/2005 | US6845245 Access parameter adaptation and packet data resource management using detailed mobile status information |
| 01/18/2005 | US6844456 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 01/18/2005 | US6844443 Hypotensive agents; cardiovascular disorders |
| 01/18/2005 | US6844437 Chemical intermediates; anticholesterol agents, antilipemic agents |
| 01/18/2005 | US6844435 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 01/18/2005 | US6844359 As inhibitors of tumor necrosis factor; for therapy of cachexia, arthritis, rheumatoid arthritis, osteoarthritis, reperfusion injury, congestive heart failure, Crohn's disease, ulcerative colitis, systemic lupus erythrematosis |
| 01/18/2005 | US6844352 1′-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4′-piperidine] hydrohalogenides |
| 01/18/2005 | US6844348 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds |
| 01/18/2005 | US6844347 Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 01/18/2005 | US6844345 Piperazine derivatives |
| 01/18/2005 | US6844343 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 01/18/2005 | US6844341 Cell cycle kinase inhibitors; such as 2-(4-(N-(2-methoxy-ethyl)-sulphamoyl)anilino)-4-(imidazo(1,2b)pyridazin-3 -yl)-pyrimidine |
| 01/18/2005 | US6844336 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity |
| 01/18/2005 | US6844335 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors |
| 01/18/2005 | US6844329 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 01/18/2005 | US6844327 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/18/2005 | US6844319 Targeting Hepatic Stellate Cells (HSC) involved in sclerotic and/or fibrotic diseases with carrier linked to amino acid sequence SRNLIDC |
| 01/18/2005 | US6844180 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 01/18/2005 | CA2269638C Ice inhibiting peptides |
| 01/13/2005 | WO2005003764A2 Assay for detecting atrial and brain natriuretic peptide prohormones |
| 01/13/2005 | WO2005003146A1 The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same |
| 01/13/2005 | WO2005003127A1 Bicyclic heteroaromatic derivatives as modulators of cxcr3 function |
| 01/13/2005 | WO2005003119A1 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same |
| 01/13/2005 | WO2005003114A1 5-fluoro-thiopen-compounds,the process for their preparation,the pharmaceutical compositions containing them and their use as metallopotenases inhibitors |
| 01/13/2005 | WO2005002672A2 Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| 01/13/2005 | WO2005002614A1 Methods and compositions for treating disorders of the extracellular matrix |
| 01/13/2005 | WO2005002606A1 Use of a single-cell protein material |
| 01/13/2005 | WO2005002605A1 Fish protein hydrolyzate |
| 01/13/2005 | WO2005002572A2 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 01/13/2005 | WO2005002559A2 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | WO2005002558A1 Preventive and/or therapeutic agent for inflammatory bowel disease |
| 01/13/2005 | WO2005002557A1 Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| 01/13/2005 | WO2005002555A2 Sirt1 modulators for manipulating cell/organism lifespan/stress response |
| 01/13/2005 | WO2004082567A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 01/13/2005 | WO2004080375A3 Vaccine therapy of atherosclerosis |
| 01/13/2005 | WO2004076406A3 Losartan potassium polymorphs and process for the preparation thereof |
| 01/13/2005 | WO2004042077A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | US20050010056 Concentrating aqueous fractions of lisinopril by reverse osmosis |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050009918 Penetration enhancer; polysaccharide gum or polyacrylic acid thickener; aliphatic alcohol or ester or liquid polyol; water; and a buffer; relieves constriction of a blood vessel in vasospasm and restores blood flow; improving microcirculation in a replanted body part. |
| 01/13/2005 | US20050009914 Increasing the production of the blood-forming hormone erythropoietin, especially for the treatment of aging- or disease-related conditions associated with decreased oxygen supply to the tissue, especially in elderly subjects, in the treatment of malignant diseases and in cardiorespiratory disorders |
| 01/13/2005 | US20050009897 Method of treatment |
| 01/13/2005 | US20050009896 Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009893 Administering a renin-angiotensin system inhibitor, particularly an angiotensin-receptor-blocker, an ACE-inhibitor, or a vasopeptidase inhibitor, especially incombination with a hypotensive agent |
| 01/13/2005 | US20050009892 Phenyloxazole derivatives lower blood triglyceride, glucose, insulin; hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity; 2-methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-(E)-4-hexenyloxy]propionic acid |
| 01/13/2005 | US20050009887 Method of resolving amlodipine racemate |
| 01/13/2005 | US20050009874 Tetrahydropyridin or piperidino heterocyclic derivatives |
| 01/13/2005 | US20050009867 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/13/2005 | US20050009861 Inverse agonist has a functional efficacy at the alpha 1 and/or alpha 5 receptor subtypes of less than -5%, and the efficacy measured at the alpha 2 and alpha 3 receptor subtypes is greater than 5%, and is preferably a 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009820 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 01/13/2005 | US20050009818 Therapeutic heterocyclic compounds |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009815 4-Aminoquinoline compounds |
| 01/13/2005 | US20050009791 Especially lysine, arginine, histidine, omithine and diaminobutyric acid; improved solubility for parenteral administration |
| 01/13/2005 | US20050009787 Complex of phosphate and ubiquinone, ascorbic acid, retinol, tocotriennol in mixture with carrier |
| 01/13/2005 | US20050009785 Heterocyclic compounds |
| 01/13/2005 | US20050009776 Using N-cyclopentyl-, 5-(N'-ethyl-)carboxamidoadenosine |
| 01/13/2005 | US20050009755 (74)(3S)-3-amino-1-(1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-4-yl)-5-methyl-2-heptanone for example; cysteine protease inhibitors; treating bone resorption diseases such as osteoporosis |
| 01/13/2005 | US20050009744 Treatment of congestive heart failure |
| 01/13/2005 | US20050009730 Sleep disorders; side effect reduction |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009140 Elongase genes and uses thereof |
| 01/13/2005 | US20050009085 44 Human secreted proteins |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008655 Useful as barrier applied to skin; chemical and radiation resistance; skin disorders; autoimmune diseases; antitumor agents; topical applying |
| 01/13/2005 | US20050008581 Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| 01/13/2005 | CA2778309A1 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | CA2778126A1 Methods of inhibiting vascular permeability and apoptosis |
| 01/13/2005 | CA2542401A1 Use of a single-cell protein material |
| 01/13/2005 | CA2542396A1 Fish protein hydrolyzate |
| 01/13/2005 | CA2532066A1 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |